hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) Kailera posts late-stage trial data

In vitro and ex vivo models 15 MullerT

A phase 2, double-blind, placebo-controlled trial randomized patients with moderate-severe PDPN to subcutaneous fulranumab or placebo

Business Description Product Portfolio Strategic Alliances or Partnerships Recent Developments Financial Details Others Others Disclaimer MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts

Nat Rev Endocrinol 2012

Retinol and riboflavin supplementation decreases the prevalence of anemia in Chinese pregnant women taking iron and folic Acid supplements